Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Graefen

Showing results (271-280 of 918) with videos related to

Pageof 92
Sort By:
Cancers|October 28, 2023
EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate CancerFabian Falkenbach, Francesca Ambrosini, Pierre Tennstedt, et al.
Scandinavian Journal of Urology|December 5, 2019
Improved patient-reported functional outcomes after nerve-sparing radical prostatectomy by using NeuroSAFE techniqueSophie D Fosså, Burkhard Beyer, Alv A Dahl, et al.
Frontiers in Surgery|January 13, 2018
AB0/Rhesus Blood Group Does Not Influence Clinicopathological Tumor Characteristics or Oncological Outcome in Patients Undergoing Radical ProstatectomySu Jung Oh, Philipp Mandel, Felix K H Chun, et al.
Urologia Internationalis|August 10, 2010
Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer SocietyAxel Heidenreich, Peter Albers, Johannes Classen, et al.
European Urology|March 5, 2013
Timing of curative treatment for prostate cancer: a systematic reviewRoderick C N van den Bergh, Peter C Albertsen, Chris H Bangma, et al.
Plos One|July 11, 2014
Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapseJan K Hennigs, Julia Müller, Matti Adam, et al.
European Urology Oncology|April 19, 2020
Intermediate-risk Prostate Cancer: Stratification and ManagementFelix Preisser, Matthew R Cooperberg, Juanita Crook, et al.
International Journal of Oncology|September 30, 2011
The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkersPierre Tennstedt, Patricia Köster, Andreas Brüchmann, et al.
European Urology|December 16, 2011
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomesStephen A Boorjian, James A Eastham, Markus Graefen, et al.
Urologic Oncology|October 27, 2019
Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysisSophie Knipper, Carlotta Palumbo, Angela Pecoraro, et al.
Pageof 92

Showing results (271-280 of 918) with videos related to

Sort By:
Pageof 92
Cancers|October 28, 2023
EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate CancerFabian Falkenbach, Francesca Ambrosini, Pierre Tennstedt, et al.
Scandinavian Journal of Urology|December 5, 2019
Improved patient-reported functional outcomes after nerve-sparing radical prostatectomy by using NeuroSAFE techniqueSophie D Fosså, Burkhard Beyer, Alv A Dahl, et al.
Frontiers in Surgery|January 13, 2018
AB0/Rhesus Blood Group Does Not Influence Clinicopathological Tumor Characteristics or Oncological Outcome in Patients Undergoing Radical ProstatectomySu Jung Oh, Philipp Mandel, Felix K H Chun, et al.
Urologia Internationalis|August 10, 2010
Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer SocietyAxel Heidenreich, Peter Albers, Johannes Classen, et al.
European Urology|March 5, 2013
Timing of curative treatment for prostate cancer: a systematic reviewRoderick C N van den Bergh, Peter C Albertsen, Chris H Bangma, et al.
Plos One|July 11, 2014
Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapseJan K Hennigs, Julia Müller, Matti Adam, et al.
European Urology Oncology|April 19, 2020
Intermediate-risk Prostate Cancer: Stratification and ManagementFelix Preisser, Matthew R Cooperberg, Juanita Crook, et al.
International Journal of Oncology|September 30, 2011
The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkersPierre Tennstedt, Patricia Köster, Andreas Brüchmann, et al.
European Urology|December 16, 2011
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomesStephen A Boorjian, James A Eastham, Markus Graefen, et al.
Urologic Oncology|October 27, 2019
Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysisSophie Knipper, Carlotta Palumbo, Angela Pecoraro, et al.
Pageof 92